Brain

Howie’s 17+ Years After VesCell(TM): Following Hemostemix’s Heart Patients

Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…

4 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA…

4 months ago

Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data

Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related dataEnhancing dementia research by integrating…

4 months ago

Countdown to the Longevity Investors Conference 2025: Where Science, Innovation, and Investment Meet in Gstaad

Zug, Switzerland--(Newsfile Corp. - September 2, 2025) - Longevity Investors, launched back in 2020 as the first industry event series…

4 months ago

Hyperfine Receives CE Mark and UKCA Approval for Optive AI™ Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software

Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European…

4 months ago

Hyperfine Receives CE Mark and UKCA Approval for Optive AI™ Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software

Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European…

4 months ago

MicroGenDX’s New Testing Platform Cuts NGS Turnaround Time to 24 Hours for Life-Saving Decisions

Adoption of Illumina's MiSeq i100 Plus accelerates results delivery to next-day from sample receipt, speeding up patient care when time…

4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL…

4 months ago

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been…

4 months ago